BIOLASE, Inc.
BIOLNASDAQHealthcare
$0.02
+$0.00(+27.39%)
Market Cap$731942
P/E Ratio—
52W High$1.94
52W Low$0.0157
BIOLASE, Inc. (BIOL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BIOL · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2024Report Date: Aug 8, 2024EPS Actual
-$0.08
Est. -$0.07 · -14.3%
Revenue
$0.01B
Est. $0.01B · -14.3%
Fiscal Period
Q3 FY2024
FY ends December
Report Date
Aug 8, 2024
After Market Close
▼ Miss EPS▼ Miss Revenue
BIOL reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2025 | Aug 6, 2025 | — | — | — | — | — | — |
| ◌ Q2 FY2025 | May 12, 2025 | — | — | — | — | — | — |
| ◌ Q1 FY2025 | Mar 19, 2025 | — | — | — | — | — | — |
| ◌ Q4 FY2024 | Nov 7, 2024 | -$0.06 | — | — | — | $0.01B | — |
| ▼ Q3 FY2024 | Aug 8, 2024 | -$0.07 | -$0.08 | -14.3% | $0.01B | $0.01B | -14.3% |
| ▼ Q2 FY2024 | May 13, 2024 | -$0.17 | -$0.36 | -111.8% | $0.01B | $0.01B | +1.3% |
| ▲ Q1 FY2024 | Mar 21, 2024 | -$2.56 | -$1.76 | +31.3% | $0.01B | $0.01B | -0.4% |
| ▼ Q4 FY2023 | Nov 9, 2023 | -$1.85 | -$3.89 | -110.3% | $0.01B | $0.01B | -19.4% |
Q3 FY2025
Aug 6, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 12, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 19, 2025
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Nov 7, 2024
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 8, 2024Miss
EPS Actual
-$0.08
EPS Est.
-$0.07
EPS Surpr.
-14.3%
Revenue
$0.01B
Q2 FY2024
May 13, 2024Miss
EPS Actual
-$0.36
EPS Est.
-$0.17
EPS Surpr.
-111.8%
Revenue
$0.01B
Q1 FY2024
Mar 21, 2024Beat
EPS Actual
-$1.76
EPS Est.
-$2.56
EPS Surpr.
+31.3%
Revenue
$0.01B
Q4 FY2023
Nov 9, 2023Miss
EPS Actual
-$3.89
EPS Est.
-$1.85
EPS Surpr.
-110.3%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.01 | $0.01 | $0.01 | 1 |
| Q3 FY2025 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q2 FY2025 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q1 FY2025 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q4 FY2024 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q3 FY2024 | $-0.07 | $-0.07 | $-0.07 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q3 FY2024 | Aug 8, 2024 | -14.3% | $0.07 | $0.06 | -8.09% |
| ▼ Q2 FY2024 | May 13, 2024 | -111.8% | $0.17 | $0.18 | +7.10% |
| ▲ Q1 FY2024 | Mar 21, 2024 | +31.3% | $0.15 | $0.15 | +0.60% |
| ▼ Q4 FY2023 | Nov 9, 2023 | -110.3% | $1.48 | $1.43 | -3.05% |
| ▼ Q3 FY2023 | Aug 10, 2023 | -67.5% | $6.56 | $6.13 | -6.55% |
| ▼ Q2 FY2023 | May 11, 2023 | -8900.0% | $19.00 | $24.00 | +26.32% |
| ▼ Q1 FY2023 | Mar 28, 2023 | -20100.0% | $37.00 | $39.00 | +5.41% |
| ▼ Q4 FY2022 | Nov 10, 2022 | -12995.2% | $141.00 | $157.00 | +11.35% |
Q3 FY2024-8.09%
Report Date
Aug 8, 2024
EPS Beat/Miss
-14.3%
Price Before
$0.07
Price After
$0.06
Q2 FY2024+7.10%
Report Date
May 13, 2024
EPS Beat/Miss
-111.8%
Price Before
$0.17
Price After
$0.18
Q1 FY2024+0.60%
Report Date
Mar 21, 2024
EPS Beat/Miss
+31.3%
Price Before
$0.15
Price After
$0.15
Q4 FY2023-3.05%
Report Date
Nov 9, 2023
EPS Beat/Miss
-110.3%
Price Before
$1.48
Price After
$1.43
Q3 FY2023-6.55%
Report Date
Aug 10, 2023
EPS Beat/Miss
-67.5%
Price Before
$6.56
Price After
$6.13
Q2 FY2023+26.32%
Report Date
May 11, 2023
EPS Beat/Miss
-8900.0%
Price Before
$19.00
Price After
$24.00
Q1 FY2023+5.41%
Report Date
Mar 28, 2023
EPS Beat/Miss
-20100.0%
Price Before
$37.00
Price After
$39.00
Q4 FY2022+11.35%
Report Date
Nov 10, 2022
EPS Beat/Miss
-12995.2%
Price Before
$141.00
Price After
$157.00
Avg Beat Reaction+0.60%
Avg Miss Reaction+4.64%
Beat Rate1 / 8 quarters
Largest Move+26.32% (Q2 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BIOL ends December
BIOLASE, Inc. (BIOL) most recently reported earnings on August 8, 2024 for Q3 FY2024, posting EPS of $-0.08 — missing the analyst consensus of $-0.07 by -14.3%. The next BIOL earnings date is expected around September 1, 2026.
Each quarter, investors track BIOL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BIOL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BIOL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BIOL earnings · 5 questionsBIOLASE, Inc.'s next earnings report is expected around September 1, 2026. BIOL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BIOL historically reports after market close (AMC).
BIOL earnings datewhen is BIOL earningsBIOL next earnings datewhen does BIOL report earningsBIOL earnings calendar
▸ Source: FMP · BIOLASE, Inc. SEC filings · US GAAP · BIOLASE, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026